MUC17

Across TCGA pan-cancer cohorts, MUC17 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated MUC17 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MUC17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MUC17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

KIRP, UCEC, and PCPG are the cancer types where MUC17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.465	0.896	<.001	36	view →
UCEC	DFS	Median	All	0.814	0.599	.001	34	view →
PCPG	OS	Median	All	0.010	0.946	<.001	12	view →
ACC	OS	Median	All	0.140	0.623	.002	12	view →
BLCA	DFS	Median	All	0.760	0.282	.018	10	view →
LIHC	OS	Median	All	0.177	0.680	<.001	9	view →
LGG	OS	Median	All	0.204	0.799	<.001	6	view →
LUSC	DFS	Median	All	0.843	0.743	.035	4	view →
COAD	OS	Median	IV	0.140	0.657	.035	3	view →
SKCM	DFS	Median	IV	0.061	0.460	.046	3	view →
PRAD	OS	Median	All	0.938	0.996	.034	2	view →
HNSC	DFS	Median	IV	0.884	0.515	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

MUC17–KIRP (OS)

Open the KIRP breakdown →